A systematic review and critical analysis of the role of graphene-based nanomaterials in cancer theranostics

dc.contributor.authorViseu, T. M. R.por
dc.contributor.authorLopes, Carla M.por
dc.contributor.authorFernandes, Eduardapor
dc.contributor.authorReal Oliveira, M. Elisabete C.D.por
dc.contributor.authorLúcio, M.por
dc.date.accessioned2019-04-23T15:24:34Z
dc.date.available2019-04-23T15:24:34Z
dc.date.issued2018-12-16
dc.date.updated2019-04-11T11:07:09Z
dc.description.abstractMany graphene-based materials (GBNs) applied to therapy and diagnostics (theranostics) in cancer have been developed. Most of them are hybrid combinations of graphene with other components (e.g., drugs or other bioactives, polymers, and nanoparticles) aiming toward a synergic theranostic effect. However, the role of graphene in each of these hybrids is sometimes not clear enough and the synergic graphene effect is not proven. The objective of this review is to elaborate on the role of GBNs in the studies evaluated and to compare the nanoformulations in terms of some of their characteristics, such as therapeutic outcomes and toxicity, which are essential features for their potential use as bionanosystems. A systematic review was carried out using the following databases: PubMed, Scopus, and ISI Web of Science (2013–2018). Additional studies were identified manually by consulting the references list of relevant reviews. Only English papers presenting at least one strategy for cancer therapy and one strategy for cancer diagnostics, and that clearly show the role of graphene in theranostics, were included. Data extraction and quality assessment was made by reviewer pairings. Fifty-five studies met the inclusion criteria, but they were too heterogeneous to combine in statistical meta-analysis. Critical analysis and discussion of the selected papers are presented.por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersionpor
dc.description.sponsorshipThis research was funded by Fundação para a Ciência e Tecnologia (FCT) in the framework of the Strategic Funding UID/FIS/04650/2013 and in the ambit of the project POCI-01-0145-FEDER-032651. E.F. acknowledges the scholarship CFUM BI-10/2018 - UID/FIS/04650/2013.por
dc.distributioninternationalpor
dc.identifier.doi10.3390/pharmaceutics10040282por
dc.identifier.issn1999-4923por
dc.identifier.urihttps://hdl.handle.net/1822/60173
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherMultidisciplinary Digital Publishing Institutepor
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147414/PTpor
dc.relationPOCI-01-0145-FEDER-032651por
dc.rightsopenAccesspor
dc.subjectCancerpor
dc.subjectGraphene oxidepor
dc.subjectGraphene quantum dotspor
dc.subjectGraphene-based materialspor
dc.subjectNano-graphenepor
dc.subjectReduced graphene oxidepor
dc.subjectSystematic reviewpor
dc.subjectTheranosticspor
dc.subject.wosScience & Technologypor
dc.titleA systematic review and critical analysis of the role of graphene-based nanomaterials in cancer theranosticspor
dc.typearticlepor
dspace.entity.typePublicationen
oaire.citationIssue4por
oaire.citationVolume10por
sdum.journalPharmaceuticspor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
pharmaceutics-10-00282-v3.pdf
Tamanho:
1.96 MB
Formato:
Adobe Portable Document Format